105 related articles for article (PubMed ID: 21385886)
1. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Yong WP; Goh BC; Soo RA; Toh HC; Ethirajulu K; Wood J; Novotny-Diermayr V; Lee SC; Yeo WL; Chan D; Lim D; Seah E; Lim R; Zhu J
Ann Oncol; 2011 Nov; 22(11):2516-2522. PubMed ID: 21385886
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Razak AR; Hotte SJ; Siu LL; Chen EX; Hirte HW; Powers J; Walsh W; Stayner LA; Laughlin A; Novotny-Diermayr V; Zhu J; Eisenhauer EA
Br J Cancer; 2011 Mar; 104(5):756-62. PubMed ID: 21285985
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue.
Novotny-Diermayr V; Sausgruber N; Loh YK; Pasha MK; Jayaraman R; Hentze H; Yong WP; Goh BC; Toh HC; Ethirajulu K; Zhu J; Wood JM
Mol Cancer Ther; 2011 Jul; 10(7):1207-17. PubMed ID: 21586629
[TBL] [Abstract][Full Text] [Related]
4. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.
Zorzi AP; Bernstein M; Samson Y; Wall DA; Desai S; Nicksy D; Wainman N; Eisenhauer E; Baruchel S
Pediatr Blood Cancer; 2013 Nov; 60(11):1868-74. PubMed ID: 23893953
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.
Chu QS; Nielsen TO; Alcindor T; Gupta A; Endo M; Goytain A; Xu H; Verma S; Tozer R; Knowling M; Bramwell VB; Powers J; Seymour LK; Eisenhauer EA
Ann Oncol; 2015 May; 26(5):973-981. PubMed ID: 25632070
[TBL] [Abstract][Full Text] [Related]
7. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U
Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
10. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Novotny-Diermayr V; Sangthongpitag K; Hu CY; Wu X; Sausgruber N; Yeo P; Greicius G; Pettersson S; Liang AL; Loh YK; Bonday Z; Goh KC; Hentze H; Hart S; Wang H; Ethirajulu K; Wood JM
Mol Cancer Ther; 2010 Mar; 9(3):642-52. PubMed ID: 20197387
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.
Eigl BJ; North S; Winquist E; Finch D; Wood L; Sridhar SS; Powers J; Good J; Sharma M; Squire JA; Bazov J; Jamaspishvili T; Cox ME; Bradbury PA; Eisenhauer EA; Chi KN
Invest New Drugs; 2015 Aug; 33(4):969-76. PubMed ID: 25983041
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
Ganai SA
Pharm Biol; 2016 Sep; 54(9):1926-35. PubMed ID: 26853619
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Cho H; Yoon DH; Kim KP; Bae KS; Kim WS; Eom HS; Kim JS; Hong JY; Kim SJ; Lee H; Kim SJ; Suh C
Invest New Drugs; 2018 Oct; 36(5):877-885. PubMed ID: 29520651
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
de Bono JS; Kristeleit R; Tolcher A; Fong P; Pacey S; Karavasilis V; Mita M; Shaw H; Workman P; Kaye S; Rowinsky EK; Aherne W; Atadja P; Scott JW; Patnaik A
Clin Cancer Res; 2008 Oct; 14(20):6663-73. PubMed ID: 18927309
[TBL] [Abstract][Full Text] [Related]
16. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
[TBL] [Abstract][Full Text] [Related]
18. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Banerji U; van Doorn L; Papadatos-Pastos D; Kristeleit R; Debnam P; Tall M; Stewart A; Raynaud F; Garrett MD; Toal M; Hooftman L; De Bono JS; Verweij J; Eskens FA
Clin Cancer Res; 2012 May; 18(9):2687-94. PubMed ID: 22553374
[TBL] [Abstract][Full Text] [Related]
19. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Brunetto AT; Ang JE; Lal R; Olmos D; Molife LR; Kristeleit R; Parker A; Casamayor I; Olaleye M; Mais A; Hauns B; Strobel V; Hentsch B; de Bono JS
Clin Cancer Res; 2013 Oct; 19(19):5494-504. PubMed ID: 24065624
[TBL] [Abstract][Full Text] [Related]
20. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.
Sumanadasa SD; Goodman CD; Lucke AJ; Skinner-Adams T; Sahama I; Haque A; Do TA; McFadden GI; Fairlie DP; Andrews KT
Antimicrob Agents Chemother; 2012 Jul; 56(7):3849-56. PubMed ID: 22508312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]